Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
1(17%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_1
1
17%
Ph phase_3
4
67%
Ph phase_2
1
17%

Phase Distribution

1

Early Stage

1

Mid Stage

4

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
1(16.7%)
Phase 2Efficacy & side effects
1(16.7%)
Phase 3Large-scale testing
4(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

6

all time

Status Distribution
Active(2)
Completed(4)

Detailed Status

Completed4
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (16.7%)
Phase 21 (16.7%)
Phase 34 (66.7%)

Trials by Status

not_yet_recruiting117%
completed467%
recruiting117%

Recent Activity

1 active trials
Showing 5 of 6
not_yet_recruitingphase_2

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

NCT05646563
recruitingphase_3

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

NCT05726916
completedphase_3

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

NCT03500549
completedphase_3

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

NCT04463056
completedphase_3

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT04060264
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05646563Phase 2

Study of NM8074 in Adult PNH Patients With Inadequate Response to Soliris

Not Yet Recruiting
NCT05726916Phase 3

Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome

Recruiting
NCT03500549Phase 3

Study to Evaluate the Efficacy and Safety of APL-2 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed
NCT04463056Phase 3

Efficacy and Safety of Elizaria® vs. Soliris® in Patients With PNH

Completed
NCT04060264Phase 3

Clinical Trial of BCD-148 and Soliris® for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
NCT04027803Phase 1

Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6